Literature DB >> 23047799

Comparison between patient-reported and clinician-observed symptoms in oncology.

Canhua Xiao1, Rosemary Polomano, Deborah Watkins Bruner.   

Abstract

BACKGROUND: Symptom assessment is critical to understand the effectiveness of cancer treatment. Traditionally, clinicians have provided the information about cancer patients' symptoms. However, current research has shown that there are discrepancies on symptom assessment results reported by patients themselves and clinicians.
OBJECTIVE: The objective of this study was to present an integrative review on studies comparing patient-reported symptoms and clinician-observed symptoms in patients with a diagnosis of cancer.
METHODS: This was a review of published articles from PubMed, CINAHL, and the Cochrane Database, using the key words symptom or toxicity, and patient-reported, patient-rated, patient-assessed or patient-evaluated, which were combined with cancer, oncology, neoplasm, or tumor.
RESULTS: Clinicians have the propensity to underestimate the incidence, severity, or distress of symptoms experienced by cancer patients. These discrepancies appear to be consistently demonstrated over time and become even more apparent when symptoms are more severe and distressing to patients. In addition, patients report both symptom frequency and severity earlier than clinicians do; patients' symptom assessments are more predictable for daily health status, whereas clinicians' symptom measurements are more related to clinical outcomes.
CONCLUSIONS: Healthcare professionals must appreciate that there can be discordance between what they perceive and what patients experience and report. Further research needs to address methodological limitations and weaknesses of existing literature. IMPLICATIONS FOR PRACTICE: Symptoms reported by patients themselves provide the necessary and different insight into cancer and its treatment, compared with those observed by clinicians. The use of patient-reported symptoms should be incorporated into routine clinical practice and not just research studies.

Entities:  

Mesh:

Year:  2013        PMID: 23047799     DOI: 10.1097/NCC.0b013e318269040f

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  40 in total

Review 1.  The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review.

Authors:  Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch
Journal:  Support Care Cancer       Date:  2015-08-28       Impact factor: 3.603

Review 2.  Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.

Authors:  Catherine Copley-Merriman; Susan Zelt; Marci Clark; Ari Gnanasakthy
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

3.  News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity.

Authors:  Ashley Wilder Smith; Sandra A Mitchell; Cheryl K De Aguiar; Claudia Moy; William T Riley; Molly V Wagster; Ellen M Werner
Journal:  Transl Behav Med       Date:  2016-09       Impact factor: 3.046

4.  Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification.

Authors:  Stephanie L Pugh; Gwen Wyatt; Raimond K W Wong; Stephen M Sagar; Bevan Yueh; Anurag K Singh; Min Yao; Phuc Felix Nguyen-Tan; Sue S Yom; Francis S Cardinale; Khalil Sultanem; D Ian Hodson; Greg A Krempl; Ariel Chavez; Alexander M Yeh; Deborah W Bruner
Journal:  J Pain Symptom Manage       Date:  2016-11-27       Impact factor: 3.612

5.  Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.

Authors:  Margaret F Bevans; Sandra A Mitchell; John A Barrett; Michael R Bishop; Richard Childs; Daniel Fowler; Michael Krumlauf; Patricia Prince; Nonniekaye Shelburne; Leslie Wehrlen; Li Yang
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-17       Impact factor: 5.742

Review 6.  Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Authors:  Tomohiro F Nishijima; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss
Journal:  Oncologist       Date:  2017-03-08

Review 7.  Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times.

Authors:  Sagar S Patel; Aaron T Gerds
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

8.  Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.

Authors:  Ann H Klopp; Anamaria R Yeung; Snehal Deshmukh; Karen M Gil; Lari Wenzel; Shannon N Westin; Kent Gifford; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Stephanie L Pugh; Lisa A Kachnic; Deborah W Bruner
Journal:  J Clin Oncol       Date:  2018-07-10       Impact factor: 44.544

9.  Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study.

Authors:  Lori Wiener; Kristin Baird; Caroline Crum; Kimberly Powers; Paul Carpenter; K Scott Baker; Margaret L MacMillan; Eneida Nemecek; Jin-Shei Lai; Sandra A Mitchell; David A Jacobsohn
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

10.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.